...current C5I therapy if their PNH is inadequately controlled or they have previously failed C5I therapy. We currently don’t have real-world claims data experience analytics to tell how pegcetacoplan may be impacting PNH therapy."
— Patrick Gleason, Pharm.D., assistant vice president of health
outcomes at Prime Therapeutics, talked with AIS’s Radar on Specialty Pharmacy
about paroxysmal nocturnal hemoglobinuria (PNH) management, and the
opportunities payers have to better manage the ultra-rare, potentially fatal
disease.
No comments:
Post a Comment